CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
1.0295
+0.0195 (1.93%)
NASDAQ · Last Trade: Jun 6th, 3:46 PM EDT
Detailed Quote
| Previous Close | 1.010 |
|---|---|
| Open | 1.010 |
| Bid | 1.020 |
| Ask | 1.030 |
| Day's Range | 1.000 - 1.070 |
| 52 Week Range | 0.7715 - 414.00 |
| Volume | 188,992 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 4,454,409 |
Chart
About CNS Pharmaceuticals, Inc. - Common Stock (CNSP)
CNS Pharmaceuticals Inc is a biotechnology company focused on developing innovative therapies for the treatment of central nervous system (CNS) cancers. The company specializes in formulating and advancing drug candidates that target various forms of brain tumors, aiming to improve treatment options and outcomes for patients faced with challenging diagnoses. Through its research and development efforts, CNS Pharmaceuticals strives to address significant unmet medical needs in the oncology sector, leveraging scientific expertise and novel approaches to bring potential new therapies to market. Read More
News & Press Releases
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Present Promising Glioblastoma Data at Brain Tumor Biotech Summit
CNS Pharmaceuticals (NASDAQ: CNSP) announced that Chief Medical Officer Sandra Silberman, M.D., Ph.D., will present at the Brain Tumor Biotech Summit hosted by Lenox Hill Hospital’s Department of Neurosurgery on June 5, 2025. Her presentation, titled “The Future and Promise of TPI 287,” will highlight CNS’s brain-penetrating taxane candidate, which has shown efficacy in glioblastoma patients, including 3 complete and 9 partial responses in a Phase 1 trial. TPI 287, which has FDA Orphan Drug Designation for gliomas, pediatric neuroblastoma, and progressive supranuclear palsy, may offer a breakthrough in treating CNS tumors by effectively crossing the blood-brain barrier.
Via Investor Brand Network · June 5, 2025
In person presentation today, Thursday, June 5th at 9:30 AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM)
Via ACCESS Newswire · June 5, 2025
Hundreds Sue Pfizer Over Birth Control Jabs Linked to Brain Tumors
American pharmaceutical and biotech company Pfizer has been sued by hundreds of American and UK women after a recent study revealed that a contraceptive injection developed by the company increased their risk of developing brain tumors significantly. Four hundred American women have already filed the lawsuit in a Florida county, and around 200 women from the UK are also considering suing the pharmaceutical firm, the Daily Mail reports.
Via Investor Brand Network · June 4, 2025
Study Finds That Kids, Young People Wait Longer to Receive a Cancer Diagnosis
A recent study conducted by experts based at University of Nottingham in the UK has revealed that young individuals afflicted by certain kinds of cancer like bone malignancies take longer before being diagnosed .
Via Investor Brand Network · June 3, 2025
Experts Say New Test for Brain Tumors is a Game-Changer
Researchers have developed a novel brain tumor test that surgical experts have dubbed a game changer. This is because the test collapses the needed time to obtain an accurate diagnosis to just hours rather than multiple weeks as has been the case.
Via Investor Brand Network · May 22, 2025
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Reports Q1 Loss, Highlights Progress on TPI 287 for Brain Cancer
CNS Pharmaceuticals (NASDAQ: CNSP) reported a Q1 2025 net loss of $4.3 million, up from $3.5 million in the prior year period, as R&D spending increased to support data analysis for its Berubicin trial. The company remains focused on advancing TPI 287, a novel taxane with the potential to treat glioblastoma by crossing the blood-brain barrier. CNS has secured Orphan Drug Designation for TPI 287 and plans to initiate a Phase 2 study in recurrent GBM by late 2025. With $13.1 million in cash at quarter-end and an additional $5 million raised in May, the company expects to fund operations into the second half of 2026.
Via Investor Brand Network · May 16, 2025
The company intends to commence the phase 2 study of its lead program, TPI 287, to treat Glioblastoma Multiforme (GBM) by year-end.
Via Stocktwits · May 16, 2025
Cash expected to fund operations into the second half of 2026
Via ACCESS Newswire · May 16, 2025
Simple Hand Motion Test Could Reveal Undetected Brain Tumor
A viral video on social media platform TikTok is popularizing a quick and easy hand test that can reportedly reveal if someone has an undiagnosed brain tumor . The British medic who demonstrated the 30-second test on the TikTok account claims that it can help individuals identify serious brain health issues that haven’t been diagnosed yet.
Via Investor Brand Network · May 14, 2025
BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional Investor
CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company focused on brain and central nervous system cancers, has priced a “reasonable best efforts” public offering with a single healthcare-focused institutional investor, raising approximately $5 million in gross proceeds. The offering includes 3,952,570 shares of common stock at $1.265 per share and accompanying Series F warrants to purchase an equal number of shares at $1.14 per share, exercisable immediately and valid for five years. A.G.P./Alliance Global Partners is acting as the sole placement agent. Proceeds will be used for working capital and general corporate purposes. Closing is expected on or about May 14, 2025.
Via Investor Brand Network · May 14, 2025
Let's delve into the US markets on Tuesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Via Chartmill · May 13, 2025
Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session.
Via Chartmill · May 13, 2025
HOUSTON, TX / ACCESS Newswire / May 13, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced the pricing of its "reasonable best efforts" public offering with a single healthcare focused institutional investor for the purchase and sale of 3,952,570 shares of common stock of the Company (the "Common Stock) (or common stock equivalents in lieu thereof), at a purchase price of $1.265 per share of Common Stock. The Company further agreed to issue to the investors Series F Common Stock purchase warrants to purchase up to 3,952,570 shares of Common Stock (the "Series F Warrants"). The Series F Warrants will have an exercise price of $1.14 per share, will be exercisable immediately following the date of their issuance and will expire in five years.
Via ACCESS Newswire · May 13, 2025
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer Indications
CNS Pharmaceuticals (NASDAQ: CNSP) announced the successful transfer of Orphan Drug Designation from Cortice Biosciences for its lead asset TPI 287, covering gliomas, pediatric neuroblastoma, and progressive supranuclear palsy. TPI 287, a microtubule-stabilizing abeotaxane, has shown potential to cross the blood-brain barrier and demonstrated encouraging results in a Phase 1 glioblastoma trial, including 3 complete and 9 partial responses among 23 evaluable patients. The company plans to initiate a Phase 2 study by year-end 2025 and highlighted the potential benefits of Orphan status, including seven years of market exclusivity upon approval.
Via Investor Brand Network · May 13, 2025
Company advancing plans to develop TPI 287, a novel, late stage abeotaxane that appears to cross the blood-brain barrier and has published clinical efficacy data in glioblastoma multiforme (GBM)
Via ACCESS Newswire · May 13, 2025
Via Benzinga · May 9, 2025
Study Reveals Early Development of Pediatric Brain Tumors in Specialized Nerve Cells
Medulloblastoma is a commonly occurring pediatric brain cancer in kids and adolescents. The cancer develops within the cerebellum, the part of the brain responsible for coordinating movement and other functions. These tumors enlarge quickly, can grow into nearby tissues, and in some cases, can metastasize. The variations in these tumors make it challenging to find appropriate treatments.
Via Investor Brand Network · May 9, 2025
AI Can Predict the Recurrence of Brain Tumors in Kids, Study Finds
A team of researchers has leveraged a technique called temporal learning to train an AI system to predict the likelihood of brain cancer recurring in kids diagnosed with gliomas. This AI model uses the magnetic resonance images periodically captured after the kids have received treatment for the gliomas.
Via Investor Brand Network · April 30, 2025
Via Benzinga · April 24, 2025
Study Identifies Key Enzyme That Could Be Targeted to Fight Brain Cancers
Researchers at Ohio State University Medical Center have identified a key enzyme that may be used to combat one of the deadliest types of brain cancer. Known as PGM3, this enzyme plays a critical role in the hexosamine biosynthesis pathway, which contributes to rapid tumor growth through protein and lipid glycosylation. Targeting PGM3 could significantly improve glioblastoma treatment outcomes.
Via Investor Brand Network · April 23, 2025
The Global Market for Brain Tumor Treatments Will Reach $7.15 Billion by 2035
The global market for brain tumor treatments is experiencing significant transformation powered by advances in immunotherapy, personalized medicine and targeted therapy. The market is projected to grow at a 7.2% CAGR to reach $7.15 billion by 2035, according to a report published by Future Market Insights.
Via Investor Brand Network · April 17, 2025
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
Via Chartmill · April 15, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Tuesday.
Via Chartmill · April 15, 2025